PureTech Health PLC (PRTC): Price and Financial Metrics

PureTech Health PLC (PRTC): $28.39

1.08 (+3.95%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add PRTC to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#250 of 493

in industry

PRTC Price/Volume Stats

Current price $28.39 52-week high $34.00
Prev. close $27.31 52-week low $17.08
Day low $26.56 Volume 600
Day high $28.39 Avg. volume 3,362
50-day MA $28.02 Dividend yield N/A
200-day MA $25.28 Market Cap 768.83M

PRTC Stock Price Chart Interactive Chart >


PureTech Health PLC (PRTC) Company Bio


PureTech Health PLC operates as a bio therapeutics company. The Company focuses on developing medicines for diseases based on insights into the biology and connectivity of the brain, immune, and gut systems. PureTech Health established the underlying programs and platforms that resulted in its broad pipeline of products and product candidates designed to treat diseases with unmet needs.


PRTC Latest News Stream


Event/Time News Detail
Loading, please wait...

PRTC Latest Social Stream


Loading social stream, please wait...

View Full PRTC Social Stream

Latest PRTC News From Around the Web

Below are the latest news stories about PURETECH HEALTH PLC that investors may wish to consider to help them evaluate PRTC as an investment opportunity.

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

BOSTON, December 22, 2023--PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Yahoo | December 22, 2023

PureTech Year End Update and Outlook for 2024

BOSTON, December 20, 2023--PureTech Year End Update and Outlook for 2024

Yahoo | December 20, 2023

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

BOSTON, December 07, 2023--PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Yahoo | December 7, 2023

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

BOSTON, November 29, 2023--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc. (Nasdaq: KRTX) ("Karuna") announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of Septemb

Yahoo | November 29, 2023

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

BOSTON, November 17, 2023--PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Ph 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Yahoo | November 17, 2023

Read More 'PRTC' Stories Here

PRTC Price Returns

1-mo N/A
3-mo -1.29%
6-mo 13.06%
1-year N/A
3-year N/A
5-year N/A
YTD 0.75%
2023 -11.66%
2022 -13.78%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!